GALT
GALECTIN THERAPEUTICS INC
Next earnings Aug 12, 2026 · consensus $-0.09 EPS
Last earnings -7.7% on 2026-05-15
$4.99
▲ +17.97%$4.99▲ +101.21%
over 1Y
L $2.08EODHDH $6.51
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+18.0%
1W+78.2%
1M+84.8%
3M+86.2%
YTD+23.2%
1Y+101.2%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
Conservative balance sheet (liabilities/equity -1.14x).
Liabilities / equity -1.14x · latest
GALECTIN THERAPEUTICS INC shows limited reported revenue.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$30.2M | -$38.4M | -$38.1M | -$42.4M | -$20.1M |
| Net income | -$30.5M | -$38.8M | -$41.1M | -$47.0M | -$30.8M |
| Diluted EPS | -$0.52 | -$0.65 | -$0.74 | -$0.76 | -$0.48 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$311M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-9.4%
FCF yield-7.3%
Quality & risk
ROIC (est.)—
Free cash flow-$23.9M
Total debt—
Net cash$17.7M
Piotroski F-Score3/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+4.2%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Reg FD disclosure2026-06-23
- 8-K Earnings results2026-05-15
- 10-Q Quarterly report2026-05-15
- 8-K Earnings results2026-03-31
- S-3 Shelf registration (potential raise)2026-03-31
- 10-K Annual report2026-03-31
- 8-K Officer / director change2026-03-17
- 8-K Officer / director change2026-01-21
- 8-K Officer / director change2026-01-12
Recent filings
all on EDGAR ↗144Filing2026-06-26open ↗144Filing2026-06-26open ↗4Period ending 2026-06-232026-06-25open ↗144Filing2026-06-23open ↗8-KPeriod ending 2026-06-232026-06-23open ↗4Period ending 2026-05-262026-05-28open ↗8-KPeriod ending 2026-05-152026-05-15open ↗10-QPeriod ending 2026-03-312026-05-15open ↗EFFECTFiling2026-04-10open ↗CORRESPFiling2026-04-08open ↗UPLOADFiling2026-04-06open ↗S-3Filing2026-03-31open ↗
Frequently asked
- Is GALECTIN THERAPEUTICS INC (GALT) a buy?
- GALT currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity -1.14x).
- What is GALECTIN THERAPEUTICS INC's quality score?
- GALT scores 57.5/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001133416, latest 10-Q filed 2026-05-15) · EODHD · as of 6/26/2026, 6:06:21 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.